विधियों की तुलना करें
चुनी हुई विधियों की आमने-सामने समीक्षा करें; भिन्नता वाली पंक्तियाँ रेखांकित हैं।
| समतुल्यता / गैर-हीनता परीक्षण× | क्रमिक / समूह क्रमिक परीक्षण डिज़ाइन× | |
|---|---|---|
| क्षेत्र | प्रयोगात्मक अभिकल्प | प्रयोगात्मक अभिकल्प |
| परिवार | Hypothesis test | Hypothesis test |
| उद्भव वर्ष≠ | 1987 | 1979 |
| प्रवर्तक≠ | Schuirmann, D.J. / EMA regulatory framework | O'Brien & Fleming; Pocock; Lan & DeMets |
| प्रकार≠ | Parametric equivalence / non-inferiority test | Adaptive stopping trial design |
| मौलिक स्रोत≠ | Schuirmann, D.J. (1987). A Comparison of the Two One-Sided Tests Procedure and the Power Approach. Journal of Pharmacokinetics and Biopharmaceutics, 15(6), 657–680. link ↗ | O'Brien, P.C. & Fleming, T.R. (1979). A Multiple Testing Procedure for Clinical Trials. Biometrics, 35(3), 549–556. DOI ↗ |
| उपनाम≠ | non-inferiority trial, bioequivalence study, active-control trial, Denklik ve Üstünlük Olmayan Çalışma (Equivalence / Non-Inferiority) | group sequential design, adaptive stopping design, Ardışık Deneme Tasarımı (Sequential / Group Sequential) |
| संबंधित≠ | 6 | 3 |
| सारांश≠ | An equivalence or non-inferiority trial is a clinical study design that tests whether a new intervention is clinically equivalent to, or no worse than, an established standard by a pre-specified margin. Codified in Schuirmann's 1987 Two One-Sided Tests (TOST) framework and embedded in EMA and FDA regulatory guidance, this design is the regulatory standard for generic drug approval and medical device testing. | Sequential and group sequential trial designs allow a study to be stopped early — or continued — based on interim analyses conducted as data accumulate. The core framework was formalised by O'Brien and Fleming in 1979 and extended by Lan and DeMets's alpha-spending approach, and it controls the overall Type I error rate across all planned looks by pre-specifying both efficacy and futility boundaries before enrolment begins. |
| ScholarGateडेटासेट ↗ |
|
|